On May 24, 2024, Biodexa Pharmaceuticals PLC successfully closed a transaction involving the exercise of Series E and Series F warrants issued in December 2023. The company entered into agreements with accredited investors, who upon exercising their existing warrants, received replacement warrants for Series G and Series H. A total of 4,036,151 warrants were exercised, resulting in the issuance of an equivalent number of American depositary shares (ADSs), each representing 400 ordinary shares. The exercise price for the replacement warrants was set at $2.50 per share. Biodexa Pharmaceuticals raised approximately $6.05 million in gross proceeds before expenses and fees. Additionally, the company issued warrants to purchase 161,446 ADSs to Ladenburg Thalmann & Co., Inc. as placement agents in connection with the transaction. The report filed with the SEC on May 28, 2024, also includes corrections to previous scrivener errors and updates on the gross proceeds from the warrant exercises.

On May 24, 2024, Biodexa Pharmaceuticals PLC successfully closed a transaction involving the exercise of Series E and Series F warrants issued in December 2023. The company entered into agreements with accredited investors, who upon exercising their existing warrants, received replacement warrants for Series G and Series H. A total of 4,036,151 warrants were exercised, resulting in the issuance of an equivalent number of American depositary shares (ADSs), each representing 400 ordinary shares. The exercise price for the replacement warrants was set at $2.50 per share. Biodexa Pharmaceuticals raised approximately $6.05 million in gross proceeds before expenses and fees. Additionally, the company issued warrants to purchase 161,446 ADSs to Ladenburg Thalmann & Co., Inc. as placement agents in connection with the transaction. The report filed with the SEC on May 28, 2024, also includes corrections to previous scrivener errors and updates on the gross proceeds from the warrant exercises.